Connection

Michael Zile to Ventricular Function, Left

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Ventricular Function, Left.
Michael Zile
Connection Strength
8.341
Ventricular Function, Left
  1. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.
    View in: PubMed
    Score: 0.545
  2. Baroreflex Activation Therapy in Patients With Heart?Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020 07 07; 76(1):1-13.
    View in: PubMed
    Score: 0.542
  3. Should We Test for Diastolic Dysfunction? How and How Often? JACC Cardiovasc Imaging. 2020 01; 13(1 Pt 2):297-309.
    View in: PubMed
    Score: 0.504
  4. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer; 28(2):320-328.
    View in: PubMed
    Score: 0.408
  5. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.397
  6. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res. 2013 Aug; 6(4):501-15.
    View in: PubMed
    Score: 0.331
  7. Hemodynamically-Guided Management of Heart?Failure Across the Ejection?Fraction Spectrum: The GUIDE-HF Trial. JACC Heart Fail. 2022 Dec; 10(12):931-944.
    View in: PubMed
    Score: 0.159
  8. Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 08 03; 10(15):e019545.
    View in: PubMed
    Score: 0.146
  9. The Vexing Problem of HFpEF?Therapeutics: Inching Toward Success. JACC Heart Fail. 2021 05; 9(5):371-373.
    View in: PubMed
    Score: 0.143
  10. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.141
  11. Pressure overload generates a cardiac-specific profile of inflammatory mediators. Am J Physiol Heart Circ Physiol. 2020 08 01; 319(2):H331-H340.
    View in: PubMed
    Score: 0.135
  12. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 02; 13(2):e006541.
    View in: PubMed
    Score: 0.132
  13. Echocardiographic Features of Patients?With Heart?Failure and Preserved?Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 12 10; 74(23):2858-2873.
    View in: PubMed
    Score: 0.130
  14. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
    View in: PubMed
    Score: 0.130
  15. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 02 04; 141(5):352-361.
    View in: PubMed
    Score: 0.130
  16. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
    View in: PubMed
    Score: 0.128
  17. Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Circ Res. 1999 Aug 20; 85(4):364-76.
    View in: PubMed
    Score: 0.128
  18. Age-Related Characteristics and Outcomes of Patients With Heart?Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):601-612.
    View in: PubMed
    Score: 0.127
  19. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 08; 21(8):974-984.
    View in: PubMed
    Score: 0.126
  20. Heart Failure With Preserved Ejection Fraction in the Young. Circulation. 2018 12 11; 138(24):2763-2773.
    View in: PubMed
    Score: 0.122
  21. Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H958-H967.
    View in: PubMed
    Score: 0.118
  22. Type of Atrial Fibrillation and Outcomes in?Patients With Heart Failure and Reduced?Ejection?Fraction. J Am Coll Cardiol. 2017 Nov 14; 70(20):2490-2500.
    View in: PubMed
    Score: 0.113
  23. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation. 2016 11 29; 134(22):1785-1787.
    View in: PubMed
    Score: 0.106
  24. Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Apr; 9(4):e002763.
    View in: PubMed
    Score: 0.101
  25. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.100
  26. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.099
  27. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol. 1995 Sep; 269(3 Pt 2):H863-8.
    View in: PubMed
    Score: 0.097
  28. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul; 8(4):717-24.
    View in: PubMed
    Score: 0.095
  29. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct; 17(10):1066-74.
    View in: PubMed
    Score: 0.095
  30. Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? J Am Coll Cardiol. 2014 Oct 07; 64(14):1535-6.
    View in: PubMed
    Score: 0.091
  31. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014 Sep; 7(5):740-51.
    View in: PubMed
    Score: 0.090
  32. The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern. JACC Cardiovasc Imaging. 2014 Sep; 7(9):870-8.
    View in: PubMed
    Score: 0.090
  33. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014 Apr; 2(2):97-112.
    View in: PubMed
    Score: 0.088
  34. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail. 2014 Apr; 2(2):123-30.
    View in: PubMed
    Score: 0.087
  35. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11; 63(5):447-56.
    View in: PubMed
    Score: 0.085
  36. Changes in diastolic function during development and correction of chronic LV volume overload produced by mitral regurgitation. Circulation. 1993 Apr; 87(4):1378-88.
    View in: PubMed
    Score: 0.082
  37. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol. 1992 Dec; 20(7):1650-60.
    View in: PubMed
    Score: 0.080
  38. Left ventricular volume determined echocardiographically by assuming a constant left ventricular epicardial long-axis/short-axis dimension ratio throughout the cardiac cycle. J Am Coll Cardiol. 1992 Oct; 20(4):986-93.
    View in: PubMed
    Score: 0.079
  39. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
    View in: PubMed
    Score: 0.078
  40. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res. 1992 Jul; 71(1):174-87.
    View in: PubMed
    Score: 0.078
  41. Effects of autonomic modulation: more than just blood pressure. J Am Coll Cardiol. 2012 Mar 06; 59(10):910-2.
    View in: PubMed
    Score: 0.076
  42. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.076
  43. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 01; 5(2):217-25.
    View in: PubMed
    Score: 0.075
  44. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991 Aug; 261(2 Pt 2):H308-18.
    View in: PubMed
    Score: 0.073
  45. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.073
  46. Left ventricular function after surgical correction of chronic mitral regurgitation. Eur Heart J. 1991 Jul; 12 Suppl B:48-51.
    View in: PubMed
    Score: 0.073
  47. Left ventricular diastolic dysfunction limits use of maximum systolic elastance as an index of contractile function. Circulation. 1991 Feb; 83(2):674-80.
    View in: PubMed
    Score: 0.071
  48. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation. 1991 Feb; 83(2):635-44.
    View in: PubMed
    Score: 0.071
  49. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011 Feb; 17(2):167-78.
    View in: PubMed
    Score: 0.069
  50. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.064
  51. A direct test of the hypothesis that increased microtubule network density contributes to contractile dysfunction of the hypertrophied heart. Am J Physiol Heart Circ Physiol. 2008 May; 294(5):H2231-41.
    View in: PubMed
    Score: 0.058
  52. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan; 155(1):113.e1-8.
    View in: PubMed
    Score: 0.056
  53. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007 Sep; 13(7):530-40.
    View in: PubMed
    Score: 0.056
  54. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec; 20(3):147-53.
    View in: PubMed
    Score: 0.049
  55. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct; 11(8):576-85.
    View in: PubMed
    Score: 0.049
  56. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005 May 10; 111(18):2306-12.
    View in: PubMed
    Score: 0.047
  57. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.041
  58. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
    View in: PubMed
    Score: 0.039
  59. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr; 123(4):707-14.
    View in: PubMed
    Score: 0.038
  60. Ensemble machine learning model identifies patients with HFpEF from matrix-related plasma biomarkers. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H798-H805.
    View in: PubMed
    Score: 0.038
  61. Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure. J Am Heart Assoc. 2022 01 18; 11(2):e024095.
    View in: PubMed
    Score: 0.038
  62. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022 03; 24(3):497-509.
    View in: PubMed
    Score: 0.038
  63. Integrating High-Sensitivity Troponin T and?Sacubitril/Valsartan Treatment in?HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.
    View in: PubMed
    Score: 0.036
  64. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol. 2001 Mar 15; 37(4):1080-4.
    View in: PubMed
    Score: 0.036
  65. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
    View in: PubMed
    Score: 0.034
  66. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
    View in: PubMed
    Score: 0.034
  67. Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF. J Am Coll Cardiol. 2020 03 31; 75(12):1501-1502.
    View in: PubMed
    Score: 0.033
  68. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
    View in: PubMed
    Score: 0.033
  69. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
    View in: PubMed
    Score: 0.030
  70. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 07; 11(7):e004962.
    View in: PubMed
    Score: 0.029
  71. Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J Am Coll Cardiol. 1998 Jan; 31(1):180-5.
    View in: PubMed
    Score: 0.028
  72. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.028
  73. Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol. 1995 May; 268(5 Pt 2):H2104-13.
    View in: PubMed
    Score: 0.024
  74. Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. Am J Physiol Cell Physiol. 2015 Jun 15; 308(12):C972-82.
    View in: PubMed
    Score: 0.024
  75. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). Circ Heart Fail. 2015 Jan; 8(1):17-24.
    View in: PubMed
    Score: 0.023
  76. Native beta-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. Circulation. 1994 Feb; 89(2):818-26.
    View in: PubMed
    Score: 0.022
  77. Structural basis for changes in left ventricular function and geometry because of chronic mitral regurgitation and after correction of volume overload. J Thorac Cardiovasc Surg. 1993 Dec; 106(6):1147-57.
    View in: PubMed
    Score: 0.021
  78. Left ventricular mechanics and myocyte function after correction of experimental chronic mitral regurgitation by combined mitral valve replacement and preservation of the native mitral valve apparatus. Circulation. 1992 Nov; 86(5 Suppl):II16-25.
    View in: PubMed
    Score: 0.020
  79. Effects of chronic tachycardia-induced cardiomyopathy on the beta-adrenergic receptor system. J Thorac Cardiovasc Surg. 1992 Oct; 104(4):1006-12.
    View in: PubMed
    Score: 0.020
  80. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. Eur Heart J. 2013 Mar; 34(9):676-83.
    View in: PubMed
    Score: 0.020
  81. Myocardial Na+,K(+)-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1992 Mar; 24(3):277-94.
    View in: PubMed
    Score: 0.019
  82. Alterations in the myocardial capillary vasculature accompany tachycardia-induced cardiomyopathy. Basic Res Cardiol. 1992 Jan-Feb; 87(1):65-79.
    View in: PubMed
    Score: 0.019
  83. Myocardial oxygen consumption and the left ventricular pressure-volume area in normal and hypertrophic canine hearts. Circulation. 1991 Sep; 84(3):1384-92.
    View in: PubMed
    Score: 0.018
  84. Dialysis-induced alterations in left ventricular filling: mechanisms and clinical significance. Am J Kidney Dis. 1991 Mar; 17(3):277-85.
    View in: PubMed
    Score: 0.018
  85. Myocardial mechanisms causing heart failure early after cardiac transplantation. Transplant Proc. 2006 Nov; 38(9):2999-3003.
    View in: PubMed
    Score: 0.013
  86. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.010
  87. Mechanisms of cardiac hypertrophy in canine volume overload. Am J Physiol. 1998 Jul; 275(1 Pt 2):H65-74.
    View in: PubMed
    Score: 0.007
  88. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. Circulation. 1997 Mar 18; 95(6):1601-10.
    View in: PubMed
    Score: 0.007
  89. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol. 1993 Oct; 25(10):1215-33.
    View in: PubMed
    Score: 0.005
  90. Left ventricular hypertrophy due to volume overload versus pressure overload. Am J Physiol. 1992 Oct; 263(4 Pt 2):H1137-44.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.